Almirall SA

ALM

Equity

ISIN ES0157097017 / Valor 3180354

BME Bolsas y Mercados Espanoles - Renta Variable (2026-06-04)

EUR 11.16+1.45%

Almirall SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Almirall SA is a Barcelona‑based pharmaceutical company that has repositioned itself as a global specialist in dermatology, developing and commercializing prescription treatments for skin conditions such as acne, rosacea, onychomycosis and other dermatoses. The company has grown its portfolio through targeted acquisitions and licensing deals — notably the 2015 purchase of Poli Group, a specialist in nail diseases, and the 2018 acquisition of several Allergan U.S. medical dermatology products including Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), Cordran Tape (fludroxycortide) and Seysara (sarecycline) — combining established brands with pipeline assets. Almirall previously developed respiratory drugs (its aclidinium inhalers were approved in Europe) but transferred its respiratory franchise to AstraZeneca in 2014; today its commercial and R&D activities are concentrated primarily on dermatology products sold in multiple international markets.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-0.18%1Y

30.4%3Y

-21.8%5Y

Performance

26.5%1Y

24.2%3Y

27.4%5Y

Volatility